^ Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). "Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance". Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
Despite this, CBD is something nobody knows much about, and certainly nobody is monitoring it properly. CBD is widely marketed as a supplement, despite the Food and Drug Administration saying it does not qualify as such (this is because it is an active ingredient in drugs which are either approved or under investigation to be approved). CBD goes largely unregulated by the agency; on the FDA’s FAQ page, a vague answer maintains there are “many factors in deciding whether or not to initiate an enforcement action.” The Department of Agriculture handles research grants and pilot programs for hemp, but that’s where its involvement ends.

Most users find that regular application provides an analgesic effect that significantly reduces localized discomfort.2 Even though CBD is most often taken for pain relief, research is showing it to be beneficial in relieving, cramps, headaches, and psoriasis. CBD’s effects can increase the natural levels of pain-relieving endocannabinoids, decrease inflammatory responses, and desensitize pain receptors.2
Cannabidiol (CBD) is one of the most abundant compounds found in cannabis. Unlike other compounds found in cannabis, CBD is legal, has no psychoactive effects, and will not make you fail a drug test. CBD should be utilized by everybody to help strengthen and maintain their physical, neurological, and psychological states for optimal living. CBD is legal in New York.

Researchers like Blessing are legitimately excited about CBD. It shows real promise in treating previously intractable disorders like schizophrenia, and without the destructive side effects of existing drugs. Still, that doesn’t mean CBD is harmless. Research on drug interactions with CBD is in its infancy, but what is known within the medical community is that CBD can cause serious problems for people taking certain classes of drugs, namely SSRIs (a group of antidepressants including Zoloft and Prozac) and opioids.
Although a range of analytical methods have been published in recent years [48], there is no general agreement on which analytical method is most suitable and accurate. Additionally, there are currently no generally accepted guidelines or certifications to determine the qualifications of cannabis labs. As a result, cannabinoid analysis can differ significantly between labs [49], even when the exact same sample is analyzed multiple times [50]. This not only poses a risk to consumers (who do not know how trust the label on their product) but may also lead to business-to-business conflicts about the quality or value of intermediate products. Additionally, inaccurate analytical results may lead to legal problems if the THC content of a CBD product unexpectedly turns out to be higher than the maximally allowed limit. It seems clear that a better agreement on the conditions for lab testing of cannabinoids is urgently needed.

Despite this, CBD is something nobody knows much about, and certainly nobody is monitoring it properly. CBD is widely marketed as a supplement, despite the Food and Drug Administration saying it does not qualify as such (this is because it is an active ingredient in drugs which are either approved or under investigation to be approved). CBD goes largely unregulated by the agency; on the FDA’s FAQ page, a vague answer maintains there are “many factors in deciding whether or not to initiate an enforcement action.” The Department of Agriculture handles research grants and pilot programs for hemp, but that’s where its involvement ends.

CBD Topical Creams

×